Abstract
Cefpiramide (CPM, SM-1652), a new cephem antibiotic, was fundamentally and clinically studied. The following results were obtained.
1. Serum and internal genital tissue levels of CPM were measured following intravenous drip infusion of 1g.
High serum levels of 30μg/ml and tissue levels of more than 4μg/g were at least maintained for 8 hours. Favourable transfer of CPM into the pelvic dead space exudate was observed.
The exudate level was 7.25μg/ml on average even at 8 hours after intravenous drip infusion.
2. A total of 6 cases comprising 4 with BARTHOLIN'S cyst, 1 with pelvic peritonitis and 1 with lymphocyst was treated with CPM at a dose of 0.5-2g twice daily by intravenous injection or intravenous drip infusion.
The clinical response was excellent in 1 case and good in 5 cases.
Side effects and abnormal laboratory findings due to the drug were not noted.
